

Clinical Trial Protocol

Iranian Registry of Clinical Trials

13 Jul 2026

Role of topical tranexamic acid in reducing perioperative blood loss in traumatic and non-traumatic patients undergoing posterior lumbar spinal surgery

Protocol summary

Study aim

To identify the effect of topical tranexamic acid on bleeding during posterior spinal surgery in traumatic and non-traumatic patients

Design

Randomized , double blind two arm parallel group clinical trial , phase 3 on 104 participant . Randlist. software was used for randomization.

Settings and conduct

Traumatic and non-traumatic patients undergoing PLS surgery in Baqiatallah Hospital, Tehran on 1399 will be enrolled. 3 gr TXA in 100 cc saline for case group.

Participants/Inclusion and exclusion criteria

Including criteria: Patients aged 18 to 75 years; Traumatic patients (during the first 3 weeks after injury); Non-traumatic patients (with a maximum of 4 levels of involvement); The need for posterior lumbar surgery
Excluding criteria: Requires emergency surgery with non-neurosurgical indications; Bleeding more than 1 liter before surgery in cases of trauma; History of thromboembolism; Treatment with anticoagulants; Treatment with antiplatelets; Treated with other drugs that disturb coagulation such as sodium valproate; Any Tranexamic acid intake before (eg polymenorrhea in women or in dentistry); Penetrating spinal trauma; Hemodynamical instability; History of seizures; Liver disfunction; Renal dysfunction; Abnormal results of laboratory coagulation tests; Patient's reluctance;

Intervention groups

Circular nurse will make solution of 3 grams of tranexamic acid in 100 ml of normal saline for the case group, which uses for repeated washing and moistening of sterile gas for packing, and in the control group, only normal saline will use. The standard treatment is normal saline alone.

Main outcome variables

Bleeding volume will be recorded after the operation.

The length of postoperative hospitalization will record by day. Coagulation laboratory tests will perform. At the follow-up visit, the patient will asked about the returning to work. Any systemic complication will be recorded.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200203046351N1**

Registration date: **2020-12-16, 1399/09/26**

Registration timing: **registered_while_recruiting**

Last update: **2020-12-16, 1399/09/26**

Update count: **0**

Registration date

2020-12-16, 1399/09/26

Registrant information

Name

Mohammad Eslamian

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 6659 6934

Email address

md.eslamian@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-12-04, 1399/09/14

Expected recruitment end date

2021-02-22, 1399/12/04

Actual recruitment start date

empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
Role of topical tranexamic acid in reducing perioperative blood loss in traumatic and non-traumatic patients undergoing posterior lumbar spinal surgery

Public title
topical tranexamic acid in perioperative blood loss of the posterior lumbar spinal surgery

Purpose
Prevention

Inclusion/Exclusion criteria
Inclusion criteria:
Patients with age between 18 to 75 years . Patients whom needs posterior lumbar spinal surgery Traumatic patients (in the first 3 weeks after injury) Non-traumatic patients (with maximum 4 spinal level envolved)
Exclusion criteria:
History of thromboembolism Emergent surgery with indications other than neurosurgical indications Treatment with other drugs that affect blood coagulation such as sodium valproate Any tranexamic acid intake before (eg polymenorrhea in women or in dentistry) Treatment with anticoagulants Treatment with antiplatelets Spinal penetrating injury Hemodynamical unstability History of epilepsy or seizure Liver malfunction Renal failure Abnormal results of laboratory coagulation tests Patient's reluctance

Age
From **18 years** old to **75 years** old

Gender
Both

Phase
3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor

Sample size
Target sample size: **104**

Randomization (investigator's opinion)
Randomized

Randomization description
By usage of Randlist software, each participant will be assigned a random number. Even numbers will enter in the intervention group and odd numbers will be the placebo group. Another person who is unaware of the randomization and has not take part in the intervention, prepares the solution for washing during the operation based on the even or odd code of the patients. The randomization method is simple and the unit is individual randomization.

Blinding (investigator's opinion)
Double blinded

Blinding description

Patients, surgeon and the anesthesia team are blinded to intervention. Based on the codes, The same operating room technician will use medication in the case group and in the control group only normal saline is used.

Placebo
Used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Baqiyatallah Hospital
Street address
No 37, Dr Sahriati Ave
City
Hamedan
Province
Hamadan
Postal code
6516676794
Approval date
2019-12-21, 1398/09/30
Ethics committee reference number
IR.BMSU.BAQ.REC.1398.001

Health conditions studied

1

Description of health condition studied
هرنی دیسک کمر
ICD-10 code
M51.26
ICD-10 code description
Other intervertebral disc displacement, lumbar region

2

Description of health condition studied
شکستگی مهره های کمری ستون فقرات
ICD-10 code
S32.009A
ICD-10 code description
Unspecified fracture of unspecified lumbar vertebra, initial encounter for closed fracture

Primary outcomes

1

Description
Intraoperative blood loss
Timepoint

At the end of the operation
Method of measurement
with use of standard anesthesia chart by ml

Secondary outcomes

1

Description
Duration of hospitalization
Timepoint
Time of discharge
Method of measurement
Questionnaire

2

Description
coagulation studies
Timepoint
At the beginning of the study and post op
Method of measurement
questionnaire

3

Description
Duration of returning to work
Timepoint
2 month post op
Method of measurement
questionnaire

Intervention groups

1

Description
Intervention group: solution of 3 gr TXA in 100 cc normal saline will use for intermittent washing and soaking sterile gases for packing.
Category
Treatment - Drugs

2

Description
Control group: Normal saline
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Baqiatallah Hospital
Full name of responsible person
Eslamian , Mohammad
Street address
Mollasadra ave

City
Tehran
Province
Tehran
Postal code
1435916471
Phone
+98 21 8755 5250
Email
md.eslamian@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Bagheiat-allah University of Medical Sciences
Full name of responsible person
Dr.Gholamhosin Alishiri
Street address
Mollasadra ave.
City
Tehran
Province
Tehran
Postal code
1435916471
Phone
+98 21 8755 5250
Email
R.bmsu@yahoo.com
Web page address
<https://research.bmsu.ac.ir/portal/home/>
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Bagheiat-allah University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Eslamian, Mohammad
Position
Non-faculty specialist physician

Latest degree
Specialist
Other areas of specialty/work
Neurosurgery
Street address
No. 19, Jamalzadeh st
City
Tehran
Province
Tehran
Postal code
1418835568
Phone
+98 21 6659 6934
Email
md.eslamian@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Mohammad Eslamian
Position
Researcher
Latest degree
Specialist
Other areas of specialty/work
Neurosurgery
Street address
Unit 10, 3rd Floor, No. 19, Etemad Alley, North
Jamalzade Ave
City
Tehran
Province
Tehran
Postal code
1418835568
Phone
+98 21 6659 6934
Fax
Email
md.eslamian@gmail.com

Person responsible for updating data

Contact

Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Eslamian, Mohammad

Position
Non-faculty specialist physician
Latest degree
Specialist
Other areas of specialty/work
Neurosurgery
Street address
No. 19, Jamalzadeh st
City
Tehran
Province
Tehran
Postal code
1418835568
Phone
+98 21 6659 6934
Email
md.eslamian@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Not applicable

Data Dictionary

Not applicable

Title and more details about the data/document

all of the data can be shared.

When the data will become available and for how long

6 months after publication

To whom data/document is available

Researchers of university centers

Under which criteria data/document could be used

Maintain data security Permission of the financing organization and the research center

From where data/document is obtainable

E-mail

What processes are involved for a request to access data/document

After submitting the request, coordination will be done with the research center of the study and the data collection center and will be sent after approval. The process will take about 2 months.

Comments